Navigation Links
Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Date:6/15/2010

re being used primarily in connection with perifosine, Aeterna Zentaris' lead oncology compound that is being developed in collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), following various positive developments announced with respect to perifosine during the first quarter of 2010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by the Company with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting Aeterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
2. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
5. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
7. AEterna Zentaris Announces Appointment of New Board Member
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
11. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Protocol Networks ... The growing team of brand-neutral, independent consultants, Protocol Networks ... Rogers explained that over the years, his company has ... Moroso, Town of Plainfield, as well as others. With ...
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Veridex, LLC announced today,that the technology used ... (CTCs) was ranked as the top medical innovation ... academic medical center. The,ranking is based on technologies ... next year., The prestigious annual recognition follows ...
... pioneer in scalable, high performance cell loading systems, ... with industry experts on the,challenges in developing cell-based ... to the industry and will be held by ... of the respected industry experts leading this live ...
... AMDL, Inc. (Amex:,ADL), a vertically integrated pharmaceutical ... today preliminary third quarter earnings and,revised 2008 guidance ... AMDL expects gross sales to be,approximately $12.4 million ... million. Gross profit is expected to be approximately,$4.9 ...
Cached Biology Technology:Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009 2Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009 3MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... The Netherlands: Ultra-fast freezing of ovarian tissue from women ... cancer treatment can lead to it being used in ... a researcher told the 25th annual conference of the ... 29 June). Dr. Sherman Silber, Director of the St. ...
... 58 km southeast of Shingu City, Japan--Deepsea Drilling Vessel ... Trough Seismogenic Zone off the Kii Peninsula of Japan. ... water depths of 2,054 meters. Following sea floor surveys, ... prevention (BOP) system into an upper section of the ...
... Amsterdam, The Netherlands: Dutch researchers have found the first evidence ... development and implantation, which was known to occur in mice ... human female embryos prior to implantation in the womb. ... of the European Society of Human Reproduction and Embryology in ...
Cached Biology News:Ovarian transplantation: New technique gives greatly improved results in this delicate operation 2First riser-drilling research operations undertaken 2Female human embryos adjust the balance of X chromosomes before implantation 2Female human embryos adjust the balance of X chromosomes before implantation 3Female human embryos adjust the balance of X chromosomes before implantation 4
Acetate Plate Sealers 100/Box...
... proteomics demands the detection of very small ... the AXIMA-CFRplus with improved resolution (20,000) and ... increased confidence in protein identification. The AXIMA-CFRplus ... automated sample target handling and the ability ...
QCPN...
... Axima range, the AXIMA-CFR provides a ... sensitivity and mass range, and offers ... reflectron time-of-flight analysis. The unique patented ... of seamless PSD, providing efficient and ...
Biology Products: